Verici Dx has secured an order from Asahi Kasei Therapeutics to provide blood-based biomarker testing for a Phase 2 clinical trial evaluating an investigational treatment designed to prevent organ rejection in transplant recipients.
The agreement includes testing using Verici Dx’s Pre-Transplant Risk Assessment (PTRA) assay, which will be used as an exploratory research tool alongside other biomarker services during the trial.
The study is evaluating pegrizeprument (VEL-101), an investigational maintenance immunosuppressive therapy being developed to prevent acute rejection in solid organ transplant recipients.
PTRA is a blood-based next generation sequencing gene expression assay incorporating an algorithm. It measures the pre-transplant expression of immune-response genes associated with early acute rejection.
The molecular data generated during the study will help researchers assess biomarker signatures linked to immune pathway activity, metabolic dysregulation and homeostasis, and examine how these factors relate to transplant outcomes in patients receiving the investigational treatment.
The research is intended to improve understanding of the biological mechanisms associated with transplant success and rejection, while examining how molecular diagnostics can support the development of new therapies.
Verici Dx Chief Executive Officer Sara Barrington said the collaboration would allow the company to contribute its expertise in transplant biomarkers and advanced molecular diagnostics to therapeutic development and clinical research.
Verici Dx Plc (LON:VRCI) is developing a complementary suite of proprietary, leading-edge tests forming a kidney transplant diagnostics platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes.








































